Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Silence Therapeutics plc       GB0008433350

SILENCE THERAPEUTICS PLC

My previous session
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Silence Therapeutics : Results of Placing

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/12/2018 | 12:28pm EST

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

For immediate release

Patisserie Holdings PLC

12 October 2018

Results of Placing to raise approximately £15.7m

Further to the earlier announcement in relation to the proposed placing of ordinary shares, the Company announces that 31,451,100 ordinary shares (the 'Placing Shares') have been placed with institutional investors and were placed at a price of 50p per share via an accelerated bookbuild (the 'Placing'). Canaccord Genuity ('Canaccord Genuity')acted as nominated adviser, sole bookrunner and broker in connection with the Placing.The Placing raised approximately £15.7 million before expenses. Application will be made for the admission of 31,451,100 ordinary shares to trading on AIM. It is expected that admission of (a) the Firm Placing Shares comprising 10,000,000 ordinary shares will become effective at 8.00 a.m. on 18 October 2018 and that dealings in the Firm Placing Shares will commence at that time and (b) the Conditional Placing Shares comprising 21,451,100 ordinary shares will become effective at 8.00 a.m. on the Business Day following the General Meeting of the Company (expected to on or around 1 November 2018) and that dealings in the Firm Placing Shares will commence at that time and the Placing Shares shall rank pari passuwith the existing issued ordinary shares of the Company.

Following completion of the Placing the Company will have 135,322,452 Ordinary Shares in issue.

Enquiries

Patisserie Holdings PLC +44 (0)121 777 7000

Luke Johnson, Executive Chairman

Paul May, Chief Executive Officer

Nomad and Broker

Canaccord Genuity Limited +44 (0)20 7523 8000

Chris Connors

Henry Fitzgerald-O'Connor

Financial Public Relations

Maitland +44 (0) 20 7379 5151

Sam Cartwright

Jonathan Cook

Disclaimer

Silence Therapeutics plc published this content on 12 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 October 2018 16:27:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SILENCE THERAPEUTICS PLC
01/16SILENCE THERAPEUTICS : SLN124 granted Orphan Drug Designation by EMA for the tre..
AQ
01/15SILENCE THERAPEUTICS : SLN124 granted Orphan Drug Designation by EMA
PU
01/09SILENCE THERAPEUTICS : Departure of Chief Financial Officer
PU
2018SILENCE THERAPEUTICS : advances next RNAi medicine
AQ
2018SILENCE THERAPEUTICS : advances next RNAi medicine
PU
2018ALNYLAM PHARMACEUTICALS : Silence Therapeutics reaches settlement and licence ag..
AQ
2018SILENCE THERAPEUTICS : US Patent Trial & Appeal Board (PTAB) Upholds Silence Pat..
AQ
2018SILENCE THERAPEUTICS : Results of Placing
PU
2018US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First..
GL
2018Silence Therapeutics Announces Receipt of a New European Notice of Intention ..
GL
More news
Financials (GBP)
Sales 2018 14,0 M
EBIT 2018 -
Net income 2018 -
Debt 2018 37,7 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,15x
EV / Sales 2019 3,23x
Capitalization 34,5 M
Chart SILENCE THERAPEUTICS PLC
Duration : Period :
Silence Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Managers
NameTitle
David Horn Solomon Chief Executive Officer & Director
Andrew John McGlashan Richards Non-Executive Chairman
Rob Quinn Chief Financial Officer
Marie W. Lindholm Head-Technology Innovation
Stephen B. Parker Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SILENCE THERAPEUTICS PLC44
IQVIA HOLDINGS INC11.13%28 233
CELLTRION, INC.--.--%23 833
LONZA GROUP12.21%21 158
INCYTE CORPORATION31.18%17 752
SEATTLE GENETICS, INC.17.42%11 010